ÂÜÀòÂÒÂ×

Marianne Uteng has held various roles in the biotechnology industry since 2020. Marianne began their career in 2020 as a Board Observer for Rappta Therapeutics. In 2021, they became a Board Observer for Amphista Therapeutics Limited and a Board Director for CatalYm GmbH. In 2021, they also began their role as Principal at Novartis Venture Fund. In 2022, they were appointed as a Board Director for Epsilogen Ltd.

Marianne Uteng obtained their PhD in Cell Biology & Biophysics from the European Molecular Biology Laboratory (EMBL) between 2003 and 2008. Prior to that, they earned their Master's degree in Biochemistry from the University of Oslo (UiO) between 1997 and 2003.